12289 results for "best fc coin sites reddit Visit Buyfc26coins.com for latest FC 26 coins news..KX6d"

in 25.23 milliseconds.

• Reference epigenome IPS02_N_NPC_mRNA-Seq data generated from KEP study

  A IPS02_N_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin)

  Dataset EGAD00001003489

• Reference epigenome IPS03_N_ENeuron_mRNA-Seq data generated from KEP study

  A IPS03_N_ENeuron_mRNA-Seq paired end data for Early neuron cells(Tuj1)

  Dataset EGAD00001003490

• Reference epigenome IPS05_X_NPC_mRNA-Seq data generated from KEP study

  A IPS05_X_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin)

  Dataset EGAD00001003492

• Reference epigenome IPS06_X_ENeuron_mRNA-Seq data generated from KEP study

  A IPS06_X_ENeuron_mRNA-Seq paired end data for Early neuron cells(Tuj1)

  Dataset EGAD00001003493

• Reference epigenome IPS02_N_NPC_smRNA-Seq data generated from KEP study

  A IPS02_N_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin)

  Dataset EGAD00001003502

• Reference epigenome IPS03_N_ENeuron_smRNA-Seq data generated from KEP study

  A IPS03_N_ENeuron_smRNA-Seq single end data for Early neuron cells(Tuj1)

  Dataset EGAD00001003503

• Reference epigenome IPS05_X_NPC_smRNA-Seq data generated from KEP study

  A IPS05_X_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin)

  Dataset EGAD00001003505

• Reference epigenome IPS06_X_ENeuron_smRNA-Seq data generated from KEP study

  A IPS06_X_ENeuron_smRNA-Seq single end data for Early neuron cells(Tuj1)

  Dataset EGAD00001003506

• Oxford Human islet ATAC-seq dataset of 5 human islets

  ATAC-seq data for 5 non-diabetic human pancreatic islet samples

  Dataset EGAD00001003759

• Benchmark and validation of whole exome sequencing of a trio and singleton for mobile element detection.

  Illumina HiSeq paired-end exome sequencing of a trio and singleton.

  Dataset EGAD00001000883

• Exome

  Exome Seq for Study EGAS00001001844

  Dataset EGAD00001002159

• Reference epigenome KNIH001 mRNA-seq data generated from KEP study

  A KNIH001 mRNA-seq paired end data for islet cells

  Dataset EGAD00001002167

• Reference epigenome KNIH002 mRNA-seq data generated from KEP study

  A KNIH002 mRNA-seq paired end data for islet cells

  Dataset EGAD00001002168

• Reference epigenome KNIH003 mRNA-seq data generated from KEP study

  A KNIH003 mRNA-seq paired end data for islet cells

  Dataset EGAD00001002169

• Reference epigenome KNIH004 mRNA-seq data generated from KEP study

  A KNIH004 mRNA-seq paired end data for islet cells

  Dataset EGAD00001002170

• Reference epigenome KNIH005 mRNA-seq data generated from KEP study

  A KNIH005 mRNA-seq paired end data for islet cells

  Dataset EGAD00001002171

• Reference epigenome KNIH006 mRNA-seq data generated from KEP study

  A KNIH006 mRNA-seq paired end data for beta cells

  Dataset EGAD00001002172

• Melanoma - Exome sequencing

  whole exome sequencing of tumor- as well as PBMC-derived DNA of five melanoma patients for identification of naturally presented patient-specific neoepitopes

  Dataset EGAD00001002731

• ATAC-Seq of human stimulated and cultured CD4+ Treg cells

  This dataset includes whole genome sequence data for ATAC-seq (42 samples) of human stimulated and cultured CD4+ Treg cells.

  Dataset EGAD00001004829

• Reference epigenome KNIH001 miRNA-seq data generated from KEP study

  A KNIH001 miRNA-seq single end data for islet cells

  Dataset EGAD00001002760

• Reference epigenome KNIH002 miRNA-seq data generated from KEP study

  A KNIH002 miRNA-seq single end data for islet cells

  Dataset EGAD00001002761

• Reference epigenome KNIH003 miRNA-seq data generated from KEP study

  A KNIH003 miRNA-seq single end data for islet cells

  Dataset EGAD00001002762

• Reference epigenome KNIH004 miRNA-seq data generated from KEP study

  A KNIH004 miRNA-seq single end data for islet cells

  Dataset EGAD00001002763

• Reference epigenome KNIH005 miRNA-seq data generated from KEP study

  A KNIH005 miRNA-seq single end data for islet cells

  Dataset EGAD00001002764

• Reference epigenome KNIH006 miRNA-seq data generated from KEP study

  A KNIH006 miRNA-seq single end data for beta cells

  Dataset EGAD00001002765

• Leeds Paired Primary and Recurrent GBM RNAseq

  Whole transcriptome, strand-directional RNAseq data for paired primary dn recurrent samples from patients with glioblastoma

  Dataset EGAD00001005224

• Melanoma post mortem analysis

  We have been applying whole genome and transcriptome sequencing across metastases collected during post mortem. Herein we show the findings for the first such patient.

  Dataset EGAD00001005072

• Reconstructed BCRs

  Computationally reconstructed B-cell receptor sequences (using BraCeR) from scRNA-seq data for all cells passing quality control.

  Dataset EGAD00001008456

• Clinical data

  Clinical data for KATHERINE: Clinical data include Treatment Arm, Invasive Disease Free Survival (IDFS), Clinical Stage at Presentation, Hormone Receptor Status, Preoperative HER2 Directed Therapy, Pathological Node.

  Dataset EGAD00001008785

• TLR7 variants in human lupus patients

  Set of 2 bam files from patients affected with Lupus. Fastq alignments for exonic variants present in TLR7 gene.

  Dataset EGAD00001008534

• Additional Sanger Sequencing and qPCR data to PSCNL samples

  Sanger sequencing and RT-qPCR data for validation used in Primary lymphomas of the central nervous system (PCNSL).

  Dataset EGAD00001008583

• ITS amplicon sequencing dataset

  This dataset contains raw ITS amplicon sequencing data for 719 sputum samples from individuals in Guangdong province, China.

  Dataset EGAD00001009817

• COMET TCRseq raw data

  This is the raw TCRseq data for the manuscript T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases.

  Dataset EGAD00001010269

• MediMer: A versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection

  Peptide-loaded MHC class I (pMHC-I) multimers have revolutionized our capabilities to monitor disease-associated T cell responses with high sensitivity and specificity. To improve the discovery of T cell receptors (TCR) targeting neoantigens of individual tumor patients with recombinant MHC molecules, we developed a peptide-loadable MHC class I platform termed MediMer. MediMers are based on soluble disulfide-stabilized β2-microglobulin/heavy chain ectodomain single-chain dimers (dsSCD) that can be easily produced in large quantities in eukaryotic cells and tailored to individual patients’ HLA allotypes with only little hands-on time. Upon transient expression in CHO-S cells together with ER-targeted BirA biotin ligase, biotinylated dsSCD are purified from the cell supernatant and are ready to use. We show that CHO-produced dsSCD are free of endogenous peptide ligands. Empty dsSCD from more than 30 different HLA-A,B,C allotypes, that were produced and validated so far, can be loaded with synthetic peptides matching the known binding criteria of the respective allotypes, and stored at low temperature without loss of binding activity. We demonstrate the usability of peptide-loaded dsSCD multimers for the detection of human antigen-specific T cells with comparable sensitivities as multimers generated with peptide-tethered β2m-HLA heavy chain single-chain trimers (SCT) and wild-type peptide-MHC-I complexes prior formed in small-scale refolding reactions. Using allotype-specific, fluorophore-labeled competitor peptides, we present a novel dsSCD-based peptide binding assay capable of interrogating large libraries of in silico predicted neoepitope peptides by flow cytometry in a high-throughput and rapid format. We discovered rare T cell populations with specificity for tumor neoepitopes and epitopes from shared tumor-associated antigens in peripheral blood of a melanoma patient including a so far unreported HLA-C*08:02-restricted NY-ESO-1-specific CD8+ T cell population. Two representative TCR of this T cell population, which could be of potential value for a broader spectrum of patients, were identified by dsSCD-guided single-cell sequencing and were validated by cognate pMHC-I multimer staining and functional responses to autologous peptide-pulsed antigen presenting cells. By deploying the novel CHO producer cell-based dsSCD MHC-I MediMer platform, we hope to significantly improve success rates for the discovery of personalized neoepitope- specific TCR in the future by being able to also cover rare HLA allotypes.

  Study EGAS50000000065

• A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients with Surgically Resectable Adenocarcinoma of the Pancreas

  This is a single-institutional, randomized, open label platform clinical trial testing various immunotherapy combinations. Patients with newly diagnosed and surgically resectable pancreatic ductal adenocarcinoma (PDA) and scheduled to undergo the Whipple procedure at Johns Hopkins Hospital were eligible to participate in this study. Criteria for determining resectability strictly followed National Comprehensive Cancer Network (NCCN) guidelines. The study consisted of 6 parts: parts 1-5 constituted the Prime Phase (see below), and part 6 was the Extended Treatment Phase. Part 1: Participants received one cycle of immunotherapy two weeks prior to undergoing the Whipple procedure. Part 2: Subjects underwent the Whipple procedure. Part 3: Subjects received a second cycle of immunotherapy 4-10 weeks following the Whipple procedure (2-4 weeks prior to adjuvant chemoradiation). Part 4: Subjects underwent chemoradiation. Part 5: Subjects received 4 additional 28-day cycles of immunotherapy beginning 1-2 months after completing chemoradiation for a total of six cycles (two before chemoradiation and 4 following chemoradiation). Eligible subjects were randomized to Arms A and B in a 1:1 ratio, stratified up-front by age (≤65, >65). Arm A participants received Cy/GVAX. Arm B participants received the combination of Cy/GVAX and nivolumab. GVAX Vaccine consists of equal numbers (2.5 x 108 each) of Panc 6.03 pcDNA1GM-CSF and Panc 10.05 pcDNA1GM-CSF combined into a single vaccination. Each vaccination consisted of six total intradermal injections. A single intravenous (IV) dose of 200 mg/m2 Cy (CytoxanR) was given one day prior to GVAX. Anti-PD-1 Therapeutic Antibody Nivolumab 480 mg every 4 weeks was administered as an intravenous infusion. The primary objective for Arms A and B was to compare IL17 expression (Th17) in vaccine-induced lymphoid aggregates between resected PDAs from patients treated with the combination of Cy/GVAX and anti-PD-1 blockade antibody vs. the treatment of Cy/GVAX alone. Secondary objectives were to assess the safety, overall survival (OS), and disease free survival (DFS) of patients treated with each of the study drug combinations, and to assess the effects of each of the immunotherapy study drug combinations on PD-L1/PD-1 associated pathways, vaccine-induced immune regulatory signatures, and peripheral and intratumoral antigen specific T cell responses. The exploratory objective was to explore the effects of therapy on tumor and peripheral blood and tumor infiltrating immune cells, and to explore potential molecular determinants of response, progression and disease stability. To these ends, tumor infiltrating immune cells (TIICs) were obtained from surgically resected tumors following the neoadjuvant treatment of the study immunotherapy. TIICs were sorted into CD3+CD4+ T cells, CD3+CD8+ T cells, CD3-CD19+ B cells, and CD3-CD19-CD11b+ myeloid cells by flow cytometry. The sorted immune cell subtype pellets were sent to the commercial vendor (Eurofins) for RNA extraction and sequencing. SMART-seq v4 Ultra Low Input mRNA Sample Prep Kit was used for library preparation with 100bp paired end reads. FASTQ files, that were returned from the vendor, are deposited here.

  Study phs003002

• Data Access Committee for Deciphering Developmental Disorders (DDD) Project

  Dac EGAC00001000282

• DAC policy The Kids Research Institute Australia

  DAC policy related to the study: Visium CytAssist Spatial Gene Expression analysis for FFPE glioblastoma samples. Committee: Emily Fletcher emily.fletcher@thekids.org.au Anya Jones anya.jones@thekids.org.au Emma Stone emma.stone@thekids.org.au

  Dac EGAC50000000734

• Brain Mapping by Integrated Neurotechnologies for Disease Studies: Human Brain Aging Imaging Study

  Compare the MRI data with amyloid PET images and cognitive data.

  Study JGAS000277

• RNA sequencing study for 8 pairs of primary NSCLCs and distant metastases

  This study is to understand of the molecular mechanisms driving metastasis.

  Study EGAS00001004078

• Whole exome sequencing study for 8 pairs of primary NSCLCs and distant metastases

  This study is to understand of the molecular mechanisms driving metastasis.

  Study EGAS00001004077

• Low coverage whole genome sequencing form CSF-derived cell free DNA

  Low coverage whole genome sequencing form CSF-derived cell free DNA for matching samples with EM-seq cohort

  Dataset EGAD50000002148

• Picuris Pueblo Genomic Project – Ancient Dataset

  Ancient individual from Picuris Pueblo. Please refer to paper for more information.

  Dataset EGAD50000001246

• WES PTCL Data

  Whole Exome Sequencing (WES) of 153 FFPE DNA samples of Peripheral T-Cell Lymphoma. Associated with "Molecular biomarkers for stratification periheral T cell lymphoma" study.

  Dataset EGAD50000001250

• APOBEC Breast Cancer Whole Genome

  Five tumor-normal human breast cancer cases driven by APOBEC mutagenesis, including normal tissue, primary, and metastatic samples for each patient.

  Dataset EGAD50000001275

• sWGS for 92 samples of mCRC

  Shallow Whole Genome Sequencing of 92 mCRC samples. Chromosomal copy number alterations analysis was performed with the samples to predict response to bevacizumab.

  Dataset EGAD50000000992

• SMPaeds PanelSeq of cfDNA at relapse with UMIs

  Deep sequencing of a targeted panel of 67 paediatric cancer related genes for cfDNA with UMIs at approximately 1500xUMI coverage.

  Dataset EGAD50000000781

• RNA-seq of murine osteosarcoma cell line genetically modified for CYR61

  Transcriptomic analysis of K7M2 murine osteosarcoma cells stably modified to overexpress or repress CYR61

  Dataset EGAD50000000747

• Whole exome sequencing data for two samples

  Whole exome sequencing of two human samples run on the Illumina HiSeq2500 platform. It contains two BAM files aligned to the refrence genoeme GRCh38.

  Dataset EGAD50000000825

• Single Cell RNA-Seq

  Examination of Sample Multiplexing Reagents for Single Cell RNA-Seq. Nine techniques applied to samples from four PDX models: #105, #177, #233, #264

  Dataset EGAD50000000216

• SAFIR02_Cytoscan

  Genomics to select patients with metastatic breast cancer for targeted therapy (microarray_cytoscan)

  Dataset EGAD00010002239